This trial is active, not recruiting.

Conditions bronchitis, chronic, cryotherapy effect
Treatment rejuvenair
Phase phase 2
Sponsor CSA Medical, Inc.
Start date February 2016
End date September 2019
Trial size 11 participants
Trial identifier NCT02483637, 012


This study evaluates the safety of RejuvenAir Cryospray therapy to treat symptomatic chronic bronchitis patients with airflow restrictions.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
RejuvenAir treatment of the right lower lobe and right main stem bronchus. Each MCS will be tailored to the bronchial area undergoing treatment and the amount of liquid nitrogen delivered will vary depending on the airway diameter.
Device: RejuvenAir

Primary Outcomes

Adverse and Serious Adverse Events
time frame: 60 days

Secondary Outcomes

Histologic appearance of bronchial biopsies in Phase A subjects
time frame: 60 days
Airway wall thickness using high resolution computed tomography (HRCT)
time frame: 3 years

Eligibility Criteria

Male or female participants from 40 years up to 75 years old.

Inclusion Criteria: - Males and females ≥40 to ≤75 years of age. - Subject is able to read, understand, and sign a written Informed Consent in order to participate in the study. - Subject agrees to continue maintenance pulmonary/COPD medications for the duration of the study. - Diagnosis of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) for a minimum of two years. (Chronic Bronchitis is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded.) - Pre-procedure post bronchodilator FEV1 of greater than or equal to 30% and less than or equal to 80% of predicted within 3 months of enrollment. - Smoking history of at least 10 pack years. - Non-smoking for a minimum of 6 months prior to consent and agrees to continue not smoking for the duration of the study. - Subject is able to adhere to and undergo 3 (4 if in Phase A) bronchoscope procedures that includes lung biopsies and multiple MCS treatments in the opinion of the investigator Exclusion Criteria: - Subject has had an acute pulmonary infection or pneumonia within prior 6 weeks of study bronchoscopy. - Subject has had a CB and/or COPD exacerbation (requiring steroids and/or antibiotics) within 6 weeks prior to study bronchoscopy, as defined by their treating physician - Subject has clinically significant bronchiectasis or other respiratory disease other than chronic bronchitis and COPD. - Diagnosis of asthma with an onset before 30 years of age - Subject has bullous emphysema characterized as large bullae >30 millimeters on CT. - Subject has had a transplant. - Subject has the inability to walk >140 meters - Subject has PaC02 >8kPa, or a PaO2<7kPa at room air. - Subject has a RVSP >45mmHg or a LVEF<45% on 2D-cardiac echo. - Subject has undergone lung surgery: pneumonectomy, lobectomy, bullectomy, lung volume reduction surgery - Subject has had a prior lung device procedure, including emphysema stent(s) implanted, lung coils, valves, lung denervation or other devices for emphysema. - Subject is unable to temporarily discontinue use of anticoagulant therapy: warfarin, Coumadin, LMWH, heparin, clopidrogel (or equal) - Subject is on >10 mg of prednisolone/day. - Subject has a serious medical condition, such as: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction in the past year, renal failure, liver disease, cerebrovascular accident within the past 6 months, uncontrolled diabetes, hypertension, autoimmune disease or uncontrolled gastric reflux - Subject is pregnant, nursing, or planning to get pregnant during study duration. - Subject has received chemotherapy within the past 6 months or is expected to receive chemotherapy during participation in this study. - Subject is or has been in another clinical investigational study within 6 weeks of baseline. - Subject has known sensitivity to medication required to perform bronchoscopy (such as lidocaine, atropine, and benzodiazepines). - Subject has been in another clinical investigational study within 6 weeks of baseline.

Additional Information

Official title A Prospective Safety and Feasibility Study of the RejuvenAir™ System Metered Cryospray Therapy for Chronic Bronchitis Patients
Description Prospective, open label, single arm study with sequential accrual of subjects with known chronic bronchitis. There are two phases to this study. Phase A will enroll up to 12 subjects and will treat a single lobe to assess safety, feasibility and histology/immunology. After review of the data by the Data Safety Monitoring Board, Phase B of the study would begin. In Phase B of the study, Phase A subjects would have their remaining two lobes treated. In addition up to 24 subjects will be enrolled and will have all upper and lower lobes treated to assess safety, feasibility and immunology.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by CSA Medical, Inc..